Use of Natriuretic Peptide for Treating Heart Failure

Abstract

The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.

1 .- 30 . (canceled) 
     
     
         31 . A pharmaceutical composition comprising:
 an infusion solution comprising:
 an aqueous solvent; 
 a pharmaceutically acceptable excipient; and 
 an effective amount of ularitide to provide a continuous infusion for a time period of at least 24 hours at a rate of at least 7.5 ng/(kgmin) to a subject weighing from about 54.5 kg to about 119.7 kg. 
   
     
     
         32 . The pharmaceutical composition of  claim 31 , wherein the pharmaceutically acceptable excipient comprises mannitol. 
     
     
         33 . The pharmaceutical composition of  claim 31 , wherein the aqueous solvent comprises an aqueous solution of 0.9% NaCl. 
     
     
         34 . The pharmaceutical composition of  claim 31 , wherein the infusion solution is sterile. 
     
     
         35 . The pharmaceutical composition of  claim 31 , wherein the infusion solution is suitable for intravenous administration. 
     
     
         36 . The pharmaceutical composition of  claim 31 , further comprising an effective amount of one or more different cardiac medicine. 
     
     
         37 . The pharmaceutical composition of  claim 31 , wherein the time period ranges between 24 hours to 120 hours. 
     
     
         38 . The pharmaceutical composition of  claim 31 , wherein the time period ranges between 24 hours to 96 hours. 
     
     
         39 . The pharmaceutical composition of  claim 31 , wherein the time period ranges between 24 hours to 72 hours. 
     
     
         40 . The pharmaceutical composition of  claim 31 , wherein the time period ranges between 24 hours to 48 hours. 
     
     
         41 . The pharmaceutical composition of  claim 31 , wherein the time period is 24 hours. 
     
     
         42 . The pharmaceutical composition of  claim 31 , wherein the time period is 48 hours. 
     
     
         43 . The pharmaceutical composition of  claim 31 , wherein the rate ranges between 7.5 ng/(kgmin) and 200 ng/(kgmin). 
     
     
         44 . The pharmaceutical composition of  claim 31 , wherein the rate ranges between 7.5 ng/(kgmin) and 100 ng/(kgmin). 
     
     
         45 . The pharmaceutical composition of  claim 31 , wherein the rate ranges between 7.5 ng/(kgmin) and 60 ng/(kgmin). 
     
     
         46 . The pharmaceutical composition of  claim 31 , wherein the rate ranges between 7.5 ng/(kgmin) and 45 ng/(kgmin). 
     
     
         47 . The pharmaceutical composition of  claim 31 , wherein the rate ranges between 7.5 ng/(kgmin) and 30 ng/(kgmin). 
     
     
         48 . The pharmaceutical composition of  claim 31 , wherein the rate is 7.5 ng/(kgmin). 
     
     
         49 . The pharmaceutical composition of  claim 31 , wherein the rate is 15 ng/(kgmin). 
     
     
         50 . The pharmaceutical composition of  claim 31 , wherein the rate is 30 ng/(kgmin).